SN
SNTI.US Senti Biosciences Inc
- Market cap
- USD 4.06M
- P/E
- -
- P/B
- 5.45x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SNTI.US undervalued?
Graham numberThe Graham number of Senti Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Senti Biosciences Inc fundamental analysis
No fundamental analysis for Senti Biosciences Inc yet.
Senti Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Senti Biosciences Inc
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-sh…
Full company profileSenti Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Senti Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 85.0K | 394K | 2.29M | 4.29M | 1.98M | 0.00 | 22.0K | 69.3K |
| Gross Profit | -14.4M | 394K | 2.29M | 4.29M | 1.98M | - | -3.62M | - |
| Operating Income | -21.8M | -24.7M | -40.4M | -70.6M | -92.7M | -61.0M | -63.7M | -51.1M |
| EBITDA | -20.4M | -22.7M | -52.3M | -66.7M | -61.3M | -54.9M | -57.8M | -39.6M |
| Net Income | -21.2M | -19.9M | -55.3M | -45.8M | -71.1M | -52.8M | -61.4M | -38.1M |
| EPS | -16 | -4.55 | -13 | -10 | -16 | -11 | -0.27 | -1.22 |
| Balance Sheet | ||||||||
| Total Assets | 35.8M | 48.3M | 96.7M | 181M | 119M | 97.8M | 51.2M | 28.4M |
| Total Liabilities | 17.9M | 107M | 36.3M | 53.5M | 52.6M | 72.2M | 45.6M | 38.0M |
| Shareholders' Equity | 18.0M | -58.7M | 60.4M | 127M | 66.9M | 25.6M | 5.59M | -9.60M |
| Cash & Short-term Investments | 17.8M | 30.5M | 56.0M | 98.6M | 35.9M | 48.3M | 16.4M | 5.55M |
| Total Debt | - | 14.0M | 22.7M | 37.1M | 37.7M | 33.6M | 28.9M | 21.6M |
| Cash Flow | ||||||||
| Operating Cash Flow | -18.4M | -24.2M | -34.6M | -34.9M | -52.4M | -41.4M | -43.4M | -37.9M |
| Capital Expenditure | 2.00M | 1.16M | 5.54M | 41.4M | 12.0M | 26.0K | 196K | 0.00 |
| Free Cash Flow | -20.4M | -25.3M | -40.2M | -76.3M | -64.4M | -41.4M | -43.6M | -37.9M |
| Ratios | ||||||||
| ROE | -117.8% | - | -91.6% | -36.0% | -106.2% | -205.8% | -1,099.3% | - |
| ROA | -59.0% | -41.1% | -57.2% | -25.3% | -59.5% | -54.0% | -119.9% | -134.3% |
| Net Profit Margin | -24,890.6% | -5,041.1% | -2,414.6% | -1,068.4% | -3,592.4% | - | -279,263.6% | -54,917.3% |
| Debt to Equity | - | - | 0.38x | 0.29x | 0.56x | 1.31x | 5.17x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Senti Biosciences Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 404K | 0.09 | - |
| 2022 | USD 5.18M | 1.18 | - |
| 2021 | USD 3.89K | 0.00 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Jul 18, 2024.
Who owns Senti Biosciences Inc
- Insiders 47.87%
- Institutions 16.73%
- Public & others 35.41%
- Shares outstanding 38.5M
- Free float 12.0M
Top funds holding SNTI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 369K | 0.96% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 95.0K | 0.25% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 24.8K | 0.06% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 20.0K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 18.8K | 0.05% | 0.00% | Sep 2026 |
Top institutions holding SNTI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 888K | 2.85% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 538K | 1.73% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 187K | 0.60% | -9.65% | Jun 2026 |
| Citadel Advisors Llc | 107K | 0.34% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 91.2K | 0.29% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 52.5K | 0.17% | 0.00% | Jun 2026 |
| Menlo Ventures Management, L.P. | 35.7K | 0.11% | 0.00% | Jun 2026 |
| Northern Trust Corp | 32.2K | 0.10% | +91.64% | Jun 2026 |
| XTX Topco Ltd | 23.6K | 0.08% | +36.66% | Jun 2026 |
| Virtu Financial LLC | 22.8K | 0.07% | 0.00% | Jun 2026 |
| UBS Group AG | 14.4K | 0.05% | +67.10% | Jun 2026 |
| State Street Corp | 10.0K | 0.03% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 7.34K | 0.02% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 4.02K | 0.01% | 0.00% | Jun 2026 |
| BlackRock Inc | 4.00K | 0.01% | -84.03% | Jun 2026 |
| Barclays PLC | 768.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 334.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 169.00 | 0.00% | +5.63% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| NEA Management Company, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Senti Biosciences Inc company profile
- Company name
- Senti Biosciences Inc
- Ticker
- SNTI.US
- Exchange
- USA Stocks
- Listed since
- Jun 9, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 39
- Fiscal year end
- December
- Address
- 2 Corporate Drive, South San Francisco, CA, United States, 94080
- Phone
- 650 239 2030
- Website
- sentibio.com
About Senti Biosciences Inc
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Senti Biosciences Inc management
7- Dr. Timothy K. Lu M.D., Ph.D.Co-Founder, CEO & Director · born 1981
- Dr. Kanya Rajangam M.D., Ph.D.President, Head of Research & Development and Chief Medical Officer · born 1973
- Dr. James J. Collins Ph.D.Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director · born 1966
- Mr. Jay CrossChief Financial Officer · born 1971
- Mr. Faraz SiddiquiSenior Vice President of Technical Operations
- Mr. Robert H. Cutler J.D.Senior VP & Head of Legal Affairs · born 1968
- Mr. Thomas P. ChungVice President of Strategic Finance & Corporate Development